User: Guest  Login
More Searchfields
Simple search
Title:

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study.

Document type:
Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study
Author(s):
Yu, Evan Y; Berry, William R; Gurney, Howard; Retz, Margitta; Conter, Henry J; Laguerre, Brigitte; Fong, Peter C C; Ferrario, Cristiano; Todenhöfer, Tilman; Gravis, Gwenaelle; Piulats, Josep M; Emmenegger, Urban; Shore, Neal D; Romano, Emanuela; Mourey, Loic; Li, Xin Tong; Poehlein, Christian H; Schloss, Charles; Appleman, Leonard J; de Bono, Johann S
Abstract:
BACKGROUND: Limited responses have been observed in patients treated with enzalutamide after disease progression on abiraterone for metastatic castration-resistant prostate cancer (mCRPC), but androgen receptor signaling impacts T-cell function. OBJECTIVE: To evaluate the efficacy and safety of pembrolizumab plus enzalutamide in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: Patients in cohort C of the phase 1b/2 KEYNOTE-365 study, who received ≥4 wk of treatment with abiraterone acetate in the prech...     »
Journal title abbreviation:
Eur Urol Oncol
Year:
2024
Journal volume:
7
Journal issue:
3
Pages contribution:
509-518
Fulltext / DOI:
doi:10.1016/j.euo.2023.10.008
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/37940446
Print-ISSN:
2588-9311
TUM Institution:
Klinik und Poliklinik für Urologie (Prof. Gschwend)
 BibTeX